CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +30.0% ·
net new positions -7.7%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | — |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | — |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | — | −1 |
| Q2 2024 | 14 | — | 3.92M | $810.09M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.74M | +135927.9% | $736.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.74M | +135927.9% | $736.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.74M | +135927.9% | $736.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.74M | +135927.9% | $736.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.74M | +135927.9% | $736.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 3.74M | +135927.9% | $736.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 3.74M | +135927.9% | $736.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.22M | +0.1% | $239.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 1.22M | +0.1% | $239.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Norges Bank ✦ (passive) | 526.31K | +2.4% | $103.67M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Marshall Wace ✦ | 309.06K | -62.6% | $60.88M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 12 | Marshall Wace ✦ | 309.06K | -62.6% | $60.88M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 273.62K | 0.0% | $53.89M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 184.69K | +0.9% | $36.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 172.91K | -73.0% | $34.06M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 172.91K | -73.0% | $34.06M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 77.38K | +51.4% | $15.24M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 18 | Baillie Gifford ✦ | 68.58K | +1.6% | $13.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Baillie Gifford ✦ | 68.58K | +1.6% | $13.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | Baillie Gifford ✦ | 68.58K | +1.6% | $13.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 44.63K | -28.3% | $8.79M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 44.63K | -28.3% | $8.79M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 19.25K | +412.5% | $3.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | Millennium Management ✦ | 18.14K | +60.2% | $3.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 25 | Citadel Advisors ✦ | 14.20K | -50.8% | $2.80M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 26 | Citadel Advisors ✦ | 14.20K | -50.8% | $2.80M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $8.73M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 555 holders, 56.84M shares, $9.32B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.04K sh · $599,711
Director · 573 sh · $163,443
Officer · 3.71K sh · $1.04M
Officer, Director · 6.50K sh · $1.82M
Director · 28.73K sh · $7.90M
Officer · 404 sh · $104,446
Officer · 1.21K sh · $311,529
Officer · 736 sh · $190,278
Officer · 4.18K sh · $1.08M
Officer · 1.27K sh · $330,055
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology